Lembas News
2 articles
growth-positive
Israeli startup Lembas unveils food additive for slimming
Israeli foodtech startup Lembas has emerged from stealth, announcing a $3.6 million pre-seed financing round led by FLORA Ventures and others. The company has developed GLP-1 Edge, a bioactive peptide aimed at regulating appetite and metabolism, which it plans to offer as a pill and integrate into food products. Lembas aims to provide an alternative to injectable GLP-1 drugs like Ozempic, targeting those who prefer non-injection methods. The product is in the R&D stage, with plans to enter the market by 2027, contingent on partnerships with food and supplement companies. The company uses AI technology to discover impactful food ingredients.
Product StageInvestment
growth-positive
Lembas Emerges from Stealth with Breakthrough Discovery in Natural GLP-1 for Weight Management
Lembas, an AI-driven bioactive peptide discovery company, has successfully raised $3.6 million in a pre-seed funding round led by FLORA Ventures. The company has emerged from stealth mode with a breakthrough in activating the GLP-1 hormone, which regulates appetite and metabolism. Lembas aims to address the $560 billion global weight management industry with its GLP-1 Edge solution, which naturally regulates appetite. The company plans to scale up and commercialize its product, expand its AI discovery platform, and deepen commercial agreements in the food and supplements industry. Lembas is backed by a university-patented technology and led by a team of experienced entrepreneurs and scientists.
InvestmentProduct StageExpandPartners
